GE Healthcare and RadNet have partnered to identify the most efficient, cost-effective approaches for breast cancer detection.
GE Healthcare and RadNet have partnered to identify the most efficient, cost-effective approaches for breast cancer detection.
Together, they will pilot test GE’s Best Pathways initiative, a breast cancer model designed to analyze clinical breast cancer detection processes, pinpoint inefficient diagnostic patterns, and discover the best ways to control costs while improving patient outcomes, both companies announced.
Best Pathways, targeted to women for whom there are few screening guidelines and frequent disparities in clinical practice, is intended to tackle the need for greater understanding around the breast cancer detection process from first screening mammograms to last biopsies.
Initiative plans include:
• determining the diagnostic cost per detected cancer,
• categorizing the types of breast cancers detected and their stage distribution,
• quantifying the number of imaging tests and biopsies needed to find each cancer, and
• determining the cost-effectiveness ratios per diagnostic case.
Patient population characteristics, such as age, risk of breast cancer development, and breast density, will be used to identify diagnostic patterns.
Previously published research in BMC Cancer revealed late diagnosis, decreased initial treatments and race are the main factors for mortality differences between wealthy and low-income breast cancer patients. The study called for more interventions targeted toward populations that lacked sufficient breast cancer services.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
ECR Mammography Study: Pre-Op CEM Detects 34 Percent More Multifocal Masses than Mammography
February 28th 2025In addition to contrast-enhanced mammography (CEM) demonstrating over a 90 percent detection rate for multifocal masses, researchers found that no significant difference between histological measurements and CEM, according to study findings presented at the European Congress of Radiology.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.